The mature mammalian kidney arises through a series of reciprocal inductive interactions between two dierent cell groups, the ureteric bud epithelium and the metanephric mesenchyme. The RET receptor tyrosine kinase is required for induction and development of the metanephric kidney. Dierential splicing at the 3' end of RET results in transcripts encoding three isoforms that dier with respect to their C-terminal 9 (RET9), 51 (RET51) or 43 (RET43) amino acids. In vitro assays have identi®ed dierences in the abilities of the RET9 and RET51 isoforms to induce dierentiation suggesting functional dierences between these proteins. We examined the relative expression levels of the three RET 3' splicing variants in developing human kidney using semi-quantitative RT ± PCR. We observed consistent expression of the RET9 and RET43 variants in kidney samples spanning 7.5 through 24 weeks gestation. At early gestational ages (7.5 ± 8.5 weeks), RET51 expression was very low (+5%) compared to RET9; however, a rapid seven fold increase in expression was detected by 9 weeks. Our data suggest that RET51 may contribute to dierentiation-related events occurring after 8.5 weeks gestation rather than to induction of the human kidney.
Introduction
The development of the mature mammalian kidney is the result of a series of reciprocal inductive interactions between ureteric bud epithelium and metanephric mesenchyme. In mouse, metanephric kidney development begins around 10.5 ± 11 days post coitum (d.p.c.) when induction of the Wolan duct produces a diverticulum, the ureteric bud (Saxen, 1987) . Metanephric mesenchyme, a dense blastema in the vicinity of the Wolan duct, induces the ureteric bud to grow and branch repeatedly giving rise to the collecting duct system. At the same time, the ureteric bud induces undierentiated metanephric mesenchyme to condense, epithelialize and ultimately dierentiate to form the glomeruli and proximal and distal convoluted tubules. The precise mechanisms of the dierentiation events are unclear. However, a number of molecules have been implicated in these inductive processes. Recent studies suggest a requirement for one such molecule, the RET receptor tyrosine kinase, in kidney induction. RET is expressed in cells and tissues derived from the neural crest, branchial arches and kidney (Pachnis et al., 1993; Tahira et al., 1990) . Expression is highest in early developmental stages decreasing to low adult levels (Avantaggiato et al., 1994; Durbec et al., 1996b; Ivanchuk et al., 1997; Pachnis et al., 1993) . In situ hybridization studies have localized RET expression to the ureteric bud in embryonic murine kidney (Pachnis et al., 1993) . Consistent with RET involvement in the induction of kidney morphogenesis, the RET knockout (7/7) mouse has kidney agenesis or severe dysgenesis (Schuchardt et al., 1994 (Schuchardt et al., , 1996 as do mice lacking glial cell line-derived neurotrophic factor (GDNF) which encodes the soluble portion of the RET ligand (Moore et al., 1996; Pichel et al., 1996; SaÂ nchez et al., 1996) . RET's proposed role as a transducer of mesenchymederived signals in kidney induction is supported by the localization of GDNF expression to the metanephric mesenchyme with highest expression in early developmental stages (Durbec et al., 1996a; Hellmich et al., 1996; Trupp et al., 1996) .
RET encodes multiple transcripts resulting from alternative splicing of 5' or 3' exons (Ivanchuk et al., 1997; Lorenzo et al., 1995; Myers et al., 1995; Tahira et al., 1990) . Skipping of exons encoding the RET extracellular domain results in products with deletions within the putative ligand binding portion of the receptor or in a truncated soluble isoform (Ivanchuk et al., 1997; Lorenzo et al., 1995) . We have previously shown that expression of RET 5' alternatively spliced variants is developmentally regulated during human kidney organogenesis with one splice variant, where exon 2 is spliced to exon 6, showing a particularly strong pattern of developmental regulation (Ivanchuk et al., 1997) . As yet, the function or signi®cance of these variant isoforms is unknown. Alternative splicing at the 3' end of RET results in transcripts encoding RET isoforms with dierent C-terminal amino acids (Myers et al., 1995; Tahira et al., 1990) . The RET gene includes 21 coding exons (Kwok et al., 1993; Myers et al., 1995) . RET exon 19 is present in all transcripts, however, dierential splicing at the 3' end of exon 19 results in transcripts where exon 19 is unspliced, spliced to exon 20 or spliced to exon 21 (Figure 1 ). These transcripts encode RET isoforms with distinct 9 (RET9), 51 (RET51) or 43 (RET43) C-terminal amino acids, respectively. Multiple polyadenylation sites and 3' UTRs are associated with these three coding variants (Myers et al, 1995; Tahira et al., 1990) . The sequences of the RET 3' alternatively spliced transcripts diverge at codon 1063 which spans the splice boundary and encodes a glycine conserved between RET9 and RET51 and an aspartic acid in RET43 (Myers et al., 1995; Tahira et al., 1990) . The ®nal common amino acid for all three isoforms is a tyrosine (Y1062) which has been shown to undergo phosphorylation on RET activation (Arighi et al., 1997; Liu et al., 1996; Lorenzo et al., 1997) . Thus, alternative splicing places Y1062 in dierent amino acid contexts in the three RET isoforms conferring it with dierent binding poten-tials. In the sequence context of RET51 for example, pY1062 has a higher binding anity for the PTB domain of the Shc adaptor protein (Arighi et al., 1997; Lorenzo et al., 1997) while the same pY in the sequence context of RET9 has a lower anity for Shc-PTB but, in addition, has anity for the Shc-SH2 domain (Arighi et al., 1997; Lorenzo et al., 1997) . There is some limited evidence of functional dierences between these RET isoforms. In recent studies Pasini et al., 1997) , more prominent neurite outgrowth has been observed in PC12 cells transfected with activated RET51 compared to activated RET9 constructs. The data are con¯icting with respect to the transforming potentials of the RET9 and RET51 isoforms.
In this study, we examined the expression of RET 3' alternatively spliced variants in a panel of human fetal kidney RNAs using a semi-quantitative reversetranscriptase polymerase chain reaction (RT ± PCR). We detected expression of transcripts representing RET9 and RET43 throughout our sample panel. Interestingly, we observed very low levels of RET51 expression in the earliest gestational ages with a dramatic seven fold increase in the relative expression level of this transcript by 9 weeks gestation. Our data suggest that the RET 3' variant encoding the RET51 isoform is not required for early kidney inductive events. However, RET51 expression may contribute to later dierentiation events responsible for shaping the mature human kidney.
Results

Expression of RET 3' alternatively spliced transcripts
We examined the expression of three dierent RET 3' alternatively spliced transcripts, which dier with respect to the C-terminal amino acids they encode, in a panel of RNAs prepared from human fetal kidneys ranging in gestational age from 7.5 through 24 weeks and human adult kidney. RNA from a medullary thyroid carcinoma cell line, TT, known to express RET at high levels, was used as a positive control (Santoro et al., 1990) . Primer pairs were selected to speci®cally amplify one of the RET 3' alternatively spliced coding variants. A single forward primer, CRT14B, that corresponds to RET exon 19 sequence common to all transcripts, was used in combination with reverse primer KRT14D, KRT20A or KRT3B (Figure 1 ) to amplify transcripts corresponding to RET9, RET51 or RET43 C-terminal amino acids respectively (Myers et al., 1995) . PCR products were electrophoresed on ethidium bromide-stained 2% agarose gels (Figure 2) . We identi®ed the RET9 (105 bp) and RET43 amplicons (180 bp) in all ages of human fetal kidney examined as well as in adult kidney and the TT cell line (positive) control. However, the RET51 amplicon (89 bp), which corresponds to transcripts in which RET exon 19 is spliced to exon 20 (Figure 1 ), was not detected or detected at very low levels in 7.5 or 8 week human fetal kidney, the earliest ages available to us ( Figure 2 ). The RET51 transcript was readily detected in the 12 week kidney sample which was the next gestational age analysed. This observation was independently con®rmed by ampli®cations using primers CRT14B (exon 19) and KRT3B (exon 21). In addition to the 180 bp product representing the exon 19/exon 21 splice which corresponds to RET43, a PCR product of 354 bp was also produced (Figure 2 ). We have shown previously that this product results from splicing of exon 19 to exon 20 to exon 21 (Myers et al., 1995) . This mRNA encodes a RET51 transcript with 3' UTR extending through a non-coding exon 21 ( Figure  1 ). Although the 180 bp amplicon corresponding to RET43 was detected in all fetal kidney samples, the 354 bp product corresponding to RET51 was detected only in samples ranging in gestational age from 12 through 24 weeks ( Figure 2 ). Our data suggested that RET51 was absent or expressed at very low levels in early kidney developmental stages and that an increase in RET51 expression occurred after 8 and before 12 weeks gestation. 
Quantitation of RET 3' alternatively spliced variants
To investigate the relative expression levels of the three RET 3' coding variants during human kidney organogenesis and to characterize the early expression of RET51, we used a semi-quantitative RT ± PCR assay similar to that previously described in quantitation of RET 5' variant transcripts (Ivanchuk et al., 1997) . We compared the expression levels of RET51 and RET43 relative to RET9, the most abundant of these transcripts, within a single RNA sample using multiplex PCR. A single forward primer in exon 19 (CRT14B) was used in combination with reverse primers in intron 19, exon 20 and exon 21 to amplify RET9, RET51 and RET43 transcripts respectively in a single reaction. Initial experiments were conducted to determine the kinetics of ampli®cation over a range of cycle numbers in order to select conditions for which ampli®cation was linear. End-labeled forward primers were included in PCRs and the quantity of PCR product was represented by the amount of radioactive incorporation. Template cDNAs were ampli®ed for 16, 20, 24, 28, 32, 36 or 40 cycles. PCR products were separated on 2% agarose gels, the appropriate bands excised and incorporated counts measured by liquid scintillation. We found that ampli®cation was linear for all products between 20 and 26 cycles of PCR ( Figure 3a ). To ensure that ampli®cation proceeded with equal eciency regardless of amount of starting template, we performed PCR using a twofold serial dilution of TT cDNA for 22, 24 and 26 cycles. The relationship between input cDNA and amount of PCR product was identi®ed for each of RET9, RET51 and RET43 when PCR proceeded for 24 cycles (Figure 3b ). Dierences in slopes were adjusted to represent a linear relationship for eciencies for all primer pairs and means and standard deviations calculated.
In our initial analyses, we chose to investigate relative expression levels of RET 3' alternatively spliced transcripts in ®ve human kidney RNA samples that spanned the range of gestational ages available (7.5, 14, 18 and 24 weeks) as well as adult kidney. Quantitation of RET51 relative to RET9 during human kidney development was performed at 24 cycles of PCR. RET43 expression was detected but at levels too low for accurate quantitation in all human kidney samples (52% of RET9 expression levels; data not shown). The reliability of 24 cycles of PCR for quantitation established in the TT cell line was con®rmed for each of these kidney samples by establishing the relationship between input cDNA and ®nal PCR product as described. The expression of RET51 relative to RET9 was assessed by comparison of incorporated counts, where RET51 product was expressed as a fraction of RET9 product. Initially, semi-quantitative assays were repeated ®ve times for each of 7.5, 14, 18 and 24 week human fetal kidney samples as well as for human adult kidney and mean expression with standard deviation calculated. These data are shown in Table 1 in bold type. RET51 expression was approximately 1/3 that of RET9 expression for the 14, 18 and 24 weeks gestation samples and adult kidney. However, our analyses detected a much lower level of expression (5 + 3%) of the RET51 transcript in the 7.5 weeks gestation kidney sample (Table 1) .
In order to characterize the early expression pattern of RET51, we examined the expression of RET51 relative to RET9 in additional fetal kidney samples between 7.5 ± 14 weeks gestation using the same semiquantitative RT ± PCR analysis (Table 1 , plain text). Expression of RET51 was found to be comparable in 7.5 and 8.5 week human fetal kidney samples at 5 + 3% and 6 + 5% that of RET9 respectively (Table 1, Figure 4) . However, by 9 weeks gestation, the expression level of RET51 had increased sevenfold to 35 + 3% that of RET9 (Table 1, Figure 4 ). Our data a b Figure 3 Representative experiments for determining optimal conditions for semi-quantitative RT ± PCR analysis of RET 3' coding variant expression in TT cells. (a) Kinetics of simultaneous ampli®cation of RET9, RET51 and RET43. Amounts of the three RET transcripts ampli®ed in a single multiplex reaction were quantitated by liquid scintillation counting of radioactivity incorporated in PCR products which had been resolved on 2% agarose gels and excised. Counts (measured in c.p.m.) were plotted relative to the number of ampli®cation cycles. The exponential reaction phase was linear between 20 and 26 cycles. Above 26 cycles, rates of ampli®cation for all RET 3' coding variant products approached plateau. (b) Con®rmation of ampli®cation eciencies of RET primers used in multiplex PCR. Representative results for 24 cycles are shown. Linear results were obtained when counts were plotted relative to substrate dilution factor for ampli®cation of all RET 3' variant transcripts. Similar slopes for the linear plots indicate comparable eciencies for all primer pairs. Dierences in slopes were accounted for in ®nal calculations using the formula (M1/M2) (calculated value) (Morrison and Gannon, 1994) suggest developmental regulation of expression of the RET51 transcript over the 7.5 ± 24 week period in the human fetal kidney. Further, we have shown that RET51 is expressed at very low levels early in gestation but represents approximately 1/3 of RET transcripts by 9 weeks gestation in the human kidney.
Discussion
The human kidney is fairly well-de®ned by 8 weeks gestation and begins to function by 11 weeks gestation (reviewed in Potter, 1972) . We have previously shown that RET expression is higher in earlier stages of kidney development (8 weeks gestation) relative to later stages (14 ± 24 weeks) (Ivanchuk et al., 1997) . RET expression levels were shown to decrease with increasing fetal age through to 24 weeks gestation and to be lowest in adult kidney. In this study, we have shown that the three RET 3' splicing variants, RET9, RET51 and RET43, are expressed during human kidney development in samples ranging in gestational age from 7.5 through 24 weeks as well as in adult kidney. RET9 is the most highly expressed while RET43 is expressed at less than 2% of RET9 levels throughout development. RET51 expression is very low (+5%) in the earliest gestational ages (7.5 ± 8.5 weeks) relative to RET9 expression in the same samples. However, a rapid sevenfold increase in RET51 expression is observed by 9 weeks gestation and similar expression levels are found in all later gestational ages examined (11 ± 24 weeks) and in adult kidney (Table 1; Figure 4 ). The relatively low expression of RET51 before 9 weeks gestation and its rapid increase in the 8.5 ± 9 week window raises the possibility that RET51 has a role in kidney development distinct from those of RET9 and RET43. By 8 weeks gestation, the permanent kidneys have taken on a recognizable form and 3 ± 5 branchings of the ureteric bud have occurred (reviewed in Potter, 1972) . A period of rapid growth and dierentiation occurs by around 10 weeks gestation during which the renal pelvis and the major and minor calyces, all products of the ureteric bud, begin to take shape. The up-regulation of RET51 expression observed here coincides with this period in which early dierentiating events occur. It is interesting to note that recent studies Pasini et al., 1997) have found a more dierentiated phenotype in PC12 cells transfected with RET51 as compared to RET9 constructs. Our data are not inconsistent with RET51 involvement in differentiation events occurring in the 8 ± 14 week period in the kidney (reviewed in Potter, 1972) . Further, this study suggests that RET51 expression is low or absent in the period during which early kidney inductive events occur when RET would not be predicted to have a dierentiating but a mitogenic role. Conversely, in NIH3T3 cells, constructs which express some activating RET mutations on the background of the RET51 isoform have a stronger transforming capacity than similar mutations in the RET9 isoform. The association of RET51 with a mitogenic role in ®broblasts and a dierentiative role in kidney and PC12 cells may suggest cell type speci®c variations in the functions or interactions of RET9 and RET51 isoforms. Consistent with these observations, van Weering and Bos (1997) have shown that RET activation induces dierent downstream signal transduction pathways in fibroblasts as compared to neural cell types which normally express RET. Thus, variability in the consequences of RET51 activation in dierent cell types in vitro may re¯ect these dierences in downstream signal transduction.
In addition to our ®ndings and those of Rossel et al. (1997) and Pasini et al. (1997) , the RET51 and RET9 isoforms have also been predicted to have dierent functional signi®cance in vivo based on information derived from a family with Hirschsprung disease (HSCR). HSCR is a congenital abnormality characterized by the absence of sympathetic neurons in the hindgut. The enteric ganglia arise from neural crest derivatives which populate the gut in the 5th to 12th week of gestation and dierentiate to form the submucosal and myenteric plexuses (Moore, 1982) . Inactivating RET mutations have been identi®ed as the underlying cause of approximately 10 ± 40% of HSCR cases (reviewed in Chakravarti, 1996; Eng and Mulligan, 1997) . By analogy with the RET (7/7) mouse, which completely lacks the enteric nervous system (Schuchardt et al., 1994) , haploinsufficiency for RET in HSCR individuals is thought to Figure 4 Developmental expression of RET 3' coding variants in human fetal kidney. Expression levels of RET51 transcripts relative to RET9 transcripts ampli®ed in the same multiplex RT ± PCR reaction for a given sample. Quantitation was performed as described in Materials and methods. Mean values shown in Table  1 are plotted (1995) have identi®ed a missense mutation present in the RET51 isoform but not in the other RET 3' coding variants. Lorenzo et al. (1997) have shown that this mutation, (M1064T), which lies within the PTB consensus binding sequence associated with Y1062, disrupts Shc phosphorylation. The RET9 and RET43 isoforms do not include the M1064T mutation and are thus unaected, however they apparently cannot compensate for absence of RET51 in development of the enteric nervous system. Thus, RET51 appears to be required for the induction or maintenance of the myenteric nerve plexus but may not be required for kidney induction which occurs in the same developmental period. Taken together, these data might suggest that RET51 preferentially, and perhaps more strongly, activates downstream dierentiation pathways in addition to mitogenic pathways in the kidney. The dierences in expression between RET9 and RET51 in kidney and the phenotype associated with mutation of only one RET isoform in HSCR suggest that these two protein forms may dier with respect to their functions and downstream signaling interactions. The RET51 isoform contains two additional tyrosine residues not present in the RET9 or RET43 isoforms (Y1092 and Y1096) (Myers et al., 1995; Takahashi et al., 1988) . The Y1096 residue is phosphorylated on activation of wildtype RET (Liu et al., 1996) and direct binding between the Grb2-SH2 interaction domain and pY1096 has been demonstrated (Borrello et al., 1994) . The unique amino acids found in RET9 and RET43 do not include tyrosine residues, however, all three isoforms do include the tyrosine residue at 1062 which can be autophosphorylated on RET activation. Splicing and sequence divergence at amino acid 1063 places this tyrosine in three dierent binding contexts in the three isoforms (Myers et al., 1995; Takahashi et al., 1988) . All three sites share a consensus sequence for interaction with the Shc-PTB domain (hydrophobic-X-N-X-pY1062) (Songyang et al., 1995) however, pY1062 is also a Shc-SH2 interaction site in RET9 only (Lorenzo et al., 1997; Rossel et al., 1997) . It is predicted that, in vivo, RET9 interaction with Shc-PTB is reduced relative to RET51 by competition with Shc-SH2 binding. It is not clear what eect these dierent binding anities have on RET function. It may be that dierent abilities to interact with PTB or SH2 domains may lead to variations in the ability of RET9 and RET51 to recruit other Shc-associated phosphoproteins to form signaling complexes. The nature of such dierences remains to be elucidated.
We have shown that the three RET 3' coding variants are expressed during human kidney development. Our data also indicate that the transcript encoding the RET51 protein is developmentally regulated and that its expression is low in early development but is upregulated before 9 weeks gestation in the human kidney. By 9 weeks gestation, expression of RET51 is consistently 1/3 that of RET9 throughout kidney development and morphogenesis. Our data are consistent with a model in which dierent RET C-terminal isoforms have distinct functional roles and provide dierent but complementary contributions to human development.
Materials and methods
Growth of TT cells
The medullary thyroid carcinoma cell line TT was grown at 378C in humidi®ed air in F12K medium supplemented with 10% fetal calf serum (Gibco-BRL Life Technologies). Cells were grown as monolayers and replated weekly.
RNA extraction
Total RNA was extracted from TT cells and human fetal kidney tissue samples ranging in gestational age from 7.5 ± 12 weeks using the TRIzol method according to manufacturer's instructions (Gibco-BRL Life Technologies). Human fetal kidney RNA samples were obtained from the Central Laboratory for Human Embryology (University of Washington, Seattle). Total RNA was isolated from adult kidney tissue and fetal kidney tissue ranging in gestational age from 14 through 24 weeks essentially by the method of Chomczynski and Sacchi (1987) .
Primer sequences
RET-speci®c primers used in these analyses were as follows: CRT14B (exon 19); KRT20A (exon 20) (Myers et al., 1995) ; KRT14D (intron 19)=5'-ATCACAGAGAG-GAAGGATAGT-3' and KRT3B (exon 21)=5'-CCTAT-CAGTGCTTTAAGTCTG-3'.
Fetal kidney, adult kidney and TT RNA analyses
One mg of total RNA was heated at 708C for 5 min and brie¯y cooled on ice. First strand cDNA was synthesized by incubating RNA templates in 50 mM Tris-HCl (pH 8.3), 8 mM MgCl 2 , 30 mM KCl, 10 mM dithiothreitol, 2 mM deoxyribonucleoside triphosphates (dNTPs), seven units avian myeloblastosis virus reverse transcriptase (Promega), 10 units human placental RNase inhibitor (Pharmacia) and 2 mM oligo dT 15 primer (Genosys) at 428C for 1 h. To inactivate the enzyme, samples were heated to 658C for 10 min and then frozen at 7208C. PCR ampli®cation of cDNA templates was performed in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.01% gelatin, 200 mM dNTPs, 1.75 mM MgCl 2 , 1 mM of each primer and 1.5 units Taq DNA polymerase (Gibco-BRL Life Technologies). Initial ampli®cation analyses to identify expression of the individual RET 3' alternatively spliced variants were performed using 1 min at 958C/1 min at 558C/1 min at 728C 1 min for 40 cycles followed by a ®nal extension of 728C for 10 min.
Semi-quantitative RT ± PCR
RT ± PCR experiments were performed in 10 mL volumes using the RT ± PCR conditions described but including 0.1 mM 32 P-end-labeled sense-strand primer. To amplify the three RET 3' alternatively spliced coding variants in a single multiplex PCR reaction, 1 mM each of RET forward primer (CRT14B) and reverse primers (KRT14D, KRT20A and KRT3B) were used. Analyses to determine the linear range of ampli®cation were performed using 1/10 of a cDNA reaction, described above, in PCR for 16, 20, 24, 28, 32, 36 or 40 cycles. PCR products were separated and visualized on ethidium bromide-stained 2% agarose gels and appropriate bands were excised. Quantitation of PCR products was performed by liquid scintillation counting of incorporated radioactivity. Plots of incorporated counts (c.p.m.) versus cycle number were used to de®ne the range of PCR cycle numbers for which ampli®cation was linear. Twofold serial dilutions of cDNA were subjected to cycles of PCR within the linear range to con®rm the number of cycles for which primers would amplify with similar eciencies, regardless of amount of starting template. PCR products were quantitated as described above. Similar slopes for the linear relationship between counts and substrate dilution factor indicated comparable amplification eciencies. Dierences in slopes were accounted for in ®nal calculations using the formula (M1/M2)/(calculated value) (Morrison and Gannon, 1994) . Based on the preliminary experiments, 24 cycles of PCR was selected for semi-quantitative RT ± PCR analysis of RET 3' alternatively spliced transcript expression in human fetal and adult kidney RNA samples.
